Literature DB >> 1345670

Brief report: a double-blind study of naltrexone in infantile autism.

M Leboyer1, M P Bouvard, J M Launay, F Tabuteau, D Waller, M Dugas, B Kerdelhue, P Lensing, J Panksepp.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1345670     DOI： 10.1007/bf01058158

Source DB:  PubMed          Journal:  J Autism Dev Disord        ISSN： 0162-3257


× No keyword cloud information.
  26 in total

1.  Naltrexone in autistic children: a double-blind and placebo-controlled study.

Authors:  M Campbell; L T Anderson; A M Small; J J Locascio; N S Lynch; M C Choroco
Journal:  Psychopharmacol Bull       Date:  1990

2.  The efficacy and safety of fenfluramine in autistic children: preliminary analysis of a double-blind study.

Authors:  M Campbell; A M Small; M Palij; R Perry; B B Polonsky; D Lukashok; L T Anderson
Journal:  Psychopharmacol Bull       Date:  1987

3.  Naltrexone in infantile autism.

Authors:  M Campbell; P Adams; A M Small; L M Tesch; E L Curren
Journal:  Psychopharmacol Bull       Date:  1988

4.  Low plasma immunoreactive beta-endorphin levels in autism.

Authors:  R Weizman; I Gil-Ad; J Dick; S Tyano; G A Szekely; Z Laron
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1988-07       Impact factor: 8.829

5.  Homologous regulation of human platelet vasopressin receptors does not occur in vivo.

Authors:  D Vittet; J M Launay; C Chevillard
Journal:  Am J Physiol       Date:  1989-12

6.  Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.

Authors:  L T Anderson; M Campbell; D M Grega; R Perry; A M Small; W H Green
Journal:  Am J Psychiatry       Date:  1984-10       Impact factor: 18.112

7.  Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects.

Authors:  R Weizman; A Weizman; S Tyano; G Szekely; B A Weissman; Y Sarne
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Endorphin activity in childhood psychosis. Spinal fluid levels in 24 cases.

Authors:  C Gillberg; L Terenius; G Lönnerholm
Journal:  Arch Gen Psychiatry       Date:  1985-08

9.  Naltrexone in autistic children: an acute open dose range tolerance trial.

Authors:  M Campbell; J E Overall; A M Small; M S Sokol; E K Spencer; P Adams; R L Foltz; K M Monti; R Perry; M Nobler
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1989-03       Impact factor: 8.829

10.  Rationale for the administration of opiate antagonists in treating infantile autism.

Authors:  S I Deutsch
Journal:  Am J Ment Defic       Date:  1986-05
View more
  18 in total

Review 1.  Autism: current theories regarding its pathogenesis and implications for rational pharmacotherapy.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

2.  CSF beta-endorphin levels in patients with infantile autism.

Authors:  S Nagamitsu; T Matsuishi; T Kisa; H Komori; M Miyazaki; T Hashimoto; Y Yamashita; E Ohtaki; H Kato
Journal:  J Autism Dev Disord       Date:  1997-04

Review 3.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

4.  Naltrexone in infantile autism.

Authors:  S L Black
Journal:  J Autism Dev Disord       Date:  1994-04

Review 5.  Opiate antagonists in children and adolescents.

Authors:  N Chabane; M Leboyer; M C Mouren-Simeoni
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

6.  Oxytocin under opioid antagonism leads to supralinear enhancement of social attention.

Authors:  Olga Dal Monte; Matthew Piva; Kevin M Anderson; Marios Tringides; Avram J Holmes; Steve W C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 7.  Medication treatment in subjects with autistic spectrum disorders.

Authors:  J K Buitelaar; S H Willemsen-Swinkels
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 8.  Pharmacotherapy of pervasive developmental disorders in children and adolescents.

Authors:  Gabriele Masi
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

9.  Basal and adrenocorticotropic hormone stimulated plasma cortisol levels among Egyptian autistic children: relation to disease severity.

Authors:  Rasha T Hamza; Doaa H Hewedi; Mona A Ismail
Journal:  Ital J Pediatr       Date:  2010-10-30       Impact factor: 2.638

10.  Cortical enlargement in autism is associated with a functional VNTR in the monoamine oxidase A gene.

Authors:  Lea K Davis; Heather C Hazlett; Amy L Librant; Peggy Nopoulos; Val C Sheffield; Joesph Piven; Thomas H Wassink
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.